KITE TO PRESENT NEW CAR T-CELL THERAPY DATA ACROSS MULTIPLE INDICATIONS AND MANUFACTURING EXPERIENCE AT EBMT 2023

KITE TO PRESENT NEW CAR T-CELL THERAPY DATA ACROSS MULTIPLE INDICATIONS AND MANUFACTURING EXPERIENCE AT EBMT 2023

Stockley Park, UK – 19 April 2023 – Kite, a Gilead Company, will support eight data presentations, including updated findings in multiple indications across its portfolio of two CAR T-cell therapies Yescarta^® (axicabtagene ciloleucel) and Tecartus^® (brexucabtagene autoleucel), and a new analysis of commercial manufacturing experience of axicabtagene ciloleucel delivery in Europe, at the European Society for Blood and Marrow Transplantation (EBMT) meeting on 23-26 April 2023 in Paris, France. 

“We are pleased to once again participate in the EBMT meeting to hear the latest developments in transplantation and share updates from our cell therapy portfolio,” said Dick Sundh, Vice President, Head of Australia, Canada and Europe (ACE), Kite. “At Kite, our focus is the delivery of cell therapies that address ongoing unmet patient need in difficult-to-treat blood cancers.  Our presentations during the meeting provide medical communities with ongoing insights into our growing body of clinical data and the delivery of CAR T-cell therapies.”

Manufacturing Experience of Axicabtagene Ciloleucel Delivery in Europe:

An analysis of commercial manufacturing experience and delivery of axicabtagene ciloleucel in Europe, providing updates on Kite’s manufacturing experience and turnaround time.

The following Kite spokespeople are available:

• Dick Sundh, Vice President, Head of ACE, Kite
• Dominique Tonelli, Executive Director, Head of Medical Affairs, ACE, Kite

For more information or to arrange an interview contact Cressida Robson on +44 7341 789 204 or cressida.robson@gilead.com. 

For more information, including a complete list of abstract titles at the meeting,

please visit: https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-information

About Kite

Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer.  As the global cell therapy leader, Kite’s therapies have treated more patients with CAR T-cell therapy than any other company.  Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial production and commercial product manufacturing.

About Gilead Sciences 

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead Sciences acquired Kite in 2017.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead and Kite’s ability to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical trials, including those involving axicabtagene ciloleucel or brexucabtagene autoleucel; Gilead and Kite’s ability to receive regulatory approvals in a timely manner or at all, including additional regulatory approvals of axicabtagene ciloleucel or brexucabtagene autoleucel, and the risk that any such approvals may be subject to significant limitations on use; the risk that physicians may not see the potential benefit of axicabtagene ciloleucel or brexucabtagene autoleucel; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead’s Quarterly Report on Form 10-K for the quarter ended December 31, 2022, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Kite and Gilead, and Kite and Gilead assume no obligation and disclaim any intent to update any such forward-looking statements.